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HMG-CoA reductase inhibitors are associated with reduced mor- Over 25 years ago, it was recognized that patients with
tality in ESRD patients. end-stage renal disease (ESRD) had markedly elevated
Background. Patients with end-stage renal disease (ESRD) rates of cardiovascular disease (CVD) [1]. Despite ad-suffer from markedly higher rates of cardiovascular disease
vances in the prevention and treatment of CVD, thethan the general population. Although therapy with 3-hydroxy-
increased risk associated with ESRD persists [2].3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibi-
tors (“statins”) has been demonstrated to reduce the mortality Although hypercholesterolemia is a risk factor for
from cardiovascular disease in patients without ESRD, only CVD in the general population, the association between
10% of patients on dialysis are treated with these medications
lipid abnormalities and CVD is less clear among ESRDby day 60 of ESRD. We determined whether the use of statins
patients. While certain atherogenic lipid abnormalitiesis associated with a reduction in cardiovascular-specific death
and total mortality in ESRD patients. are present in ESRD patients, including elevations in
Methods. Data were analyzed from the U.S. Renal Data serum triglyceride, very-low density lipoprotein (VLDL)
System Dialysis Morbidity and Mortality Wave-2 study, a co- and intermediate density lipoprotein (IDL) cholesterolhort of randomly selected patients who were initiating dialysis
and reductions in high density lipoprotein (HDL) choles-in 1996. Information about the use of statins as well as other
terol, levels of total cholesterol and low-density lipopro-baseline characteristics was abstracted from the patients’ dial-
ysis records by dialysis personnel. Cox proportional hazards tein (LDL) cholesterol are actually lower than those of
models were developed to determine the association between persons without renal failure [3–5].
use of statins at baseline and subsequent risk of mortality, with Treatment of hypercholesterolemia with HMG-CoAadjustment for known mortality risk factors.
reductase inhibitors (“statins”) has been shown to reduceResults. Follow-up data were available for 3716 patients
through July 1998. At baseline, 362 (9.7%) of patients were both total mortality and cardiovascular mortality in pa-
using statins. These patients had a mortality rate of 143/1000 tients without ESRD [6–8], both in patients with [6, 7]
person-years, compared with a rate of 202/1000 person-years and without [8, 9] documented CVD. Because lipid ab-
for patients not using statins. Statin use was independently
normalities in ESRD patients differ from patients with-associated with a reduced risk of total mortality [relative risk
out ESRD, the beneficial effects of statins shown in large(RR)  0.68, 95% confidence interval (CI)  0.54, 0.87] as
well as cardiovascular-specific mortality (RR 0.64, 95% CI randomized control trials of non-ESRD patients may
0.45, 0.91). In contrast, the use of fibrates was not associated not be applicable to patients with ESRD.
with reduced mortality (RR  1.29). Although fewer than 10% of dialysis patients are pre-Conclusions. Statin use was associated with a reduction in
scribed statins by day 60 of ESRD, several small short-cardiovascular-specific death and total mortality in patients on
dialysis. term trials of statins in patients with ESRD have shown
that they can be used safely in this patient population,
and that they cause potentially beneficial changes in lipo-
protein profiles [10–16]. To date, however, there have
been no studies specifically examining the association
between use of statins and mortality from cardiovascularKey words: hypercholesterolemia, cardiovascular disease, end-stage re-
nal disease, USRDS Wave 2, dialysis, blood pressure, lipoprotein. disease in the ESRD population. We utilized data from
the United States Renal Data System Dialysis MorbidityReceived for publication April 9, 2001
and Mortality Study Wave 2 (USRDS DMMS-2) to as-and in revised form August 7, 2001
Accepted for publication August 16, 2001 sess the association between the use of statins and mor-
tality from cardiovascular disease. 2002 by the International Society of Nephrology
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METHODS tween statins and cardiovascular death. Although DMMS
Wave 2 also recorded LDL and HDL cholesterol levelsSubjects
on some patients, they were not included in our analysisA secondary analysis of data from the USRDS DMMS
due to the high percentage (83%) of missing values.Wave 2 was performed; details of the studies performed
by the USRDS are described elsewhere [17]. Briefly, Outcome measurements
the USRDS collects demographic and clinical data on
Survival status and cause of death were linked to thepatients who have survived more than 90 days on dialysis.
DMMS Wave 2 data from the USRDS Patients StandardDMMS Wave 2 was a prospective cohort study that in-
Analysis File (SAF) via unique patient identifiers as-cluded all eligible patients initiating peritoneal dialysis
signed by the USRDS. The date and cause of death listedand a 20% random sample of patients initiating hemodi-
in a patient’s SAF was obtained from a form submitted toalysis in 1996 and early 1997. Patients were sampled from
the USRDS by the patient’s nephrologist (form HCFAamong 25% of the dialysis units listed in the December
2746). Patient survival status was complete through July1993 Master List in addition to all new dialysis units
1998. For the purposes of this analysis, cardiovascularopening after January 1, 1994. The USRDS excluded
death was defined a priori as death from one of thepatients from DMMS Wave 2 if they were younger than
following causes: myocardial infarction, atherosclerotic18 years, were home dialysis patients, or if they had
heart disease, cardiomyopathy, cardiac arrhythmia, orpreviously received a kidney transplant. Dialysis mod-
cardiac arrest.ality was determined on day 60 of renal replacement
therapy. For the purposes of this study, data from all Statistical analysis
patients who participated in DMMS Wave 2 were in-
The Cox proportional hazards model for censored sur-cluded in our analysis.
vival data was used to assess the association between
baseline statin use and mortality, independent of otherData collection
predictors of survival. Adjustment variables were chosenBaseline and follow-up patient data were abstracted
for the multivariate regression model based on the possi-by dialysis facility personnel from the patients’ medical
bility that the covariate of interest may be associatedrecords. For the purposes of this analysis, the following
with or may confound the relationship between statindemographic characteristics were included: age, race
use and the risk of CV mortality. Formal tests as well(black, white, other), and gender. Clinical characteris-
as graphic methods were used to verify the existence oftics included: dialysis modality (hemodialysis, peritoneal
proportional hazards. Further, residual diagnostics weredialysis, transplant), cause of ESRD (diabetes, hyper-
used to identify outlying points and to model the correcttension, glomerulonephritis, and “other”), history of dia-
functional form of adjustment variables. Estimated rela-betes, history of cardiovascular disease (coronary artery
tive risks (RR) along with corresponding 95% confi-disease, myocardial infarction, coronary angioplasty, cor-
dence intervals (CI) and P values for two-sided tests ofonary artery bypass surgery, cardiac arrest, congestive
association are reported for all regression covariates.heart failure, or stroke) and history of smoking (current,
To improve the generalizability of these results theformer, or never). These clinical characteristics, includ-
patients were not censored at the time of transplantation.ing cardiac history, were determined by dialysis person-
Patients selected to receive a renal transplant are gener-nel through review of notations in the patients’ medical
ally healthier when compared to typical dialysis patients;charts and through interviews with the patients them-
by excluding these patients, our study results would onlyselves. Dialysis personnel also recorded whether the pa-
be applicable to a less healthy group of individuals. Fur-tient was believed to be “undernourished or cachectic”
ther, censoring patients at the time of transplantation(a subjective impression). In addition, a maximum of 15
would introduce informative censoring into the analysis,medications prescribed to each patient at the study start
leading to potentially biased results. Hence transplanta-date (day 60 of dialysis) were recorded. From this list, the
tion, along with hemodialysis and peritoneal dialysis,use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
were included as valid treatment modalities during statis-CoA) reductase inhibitors, fibrates, angiotensin-convert-
tical analyses. To adjust for changes in treatment mod-ing enzyme (ACE) inhibitors, beta blockers, and calcium
ality during the follow-up period, the modality variablechannel blockers was determined. Relevant laboratory
was entered into the presented models as a time-depen-data for each patient at the start of the study included
dent covariate. With the use of this time-dependent co-serum albumin, triglycerides, and cholesterol. Triglycer-
variate, patients were not censored as they changed mod-ide and cholesterol were abstracted from the USRDS
ality, but instead continued to contribute time at risk fordatabase for descriptive purposes only. They were not
a given modality for the amount of time they underwentassessed as independent predictors of mortality in this
analysis because they likely mediate the relationship be- that particular modality.
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Table 1. Patient characteristics at the time of initial data collection characteristics are presented in Table 2. The use of statins
(N  3716)
was associated with a 32% lower adjusted relative risk
Statin users Non-users (aRR) of death (aRR  0.68; 95% CI  0.53, 0.86; P 
Characteristic (N362) (N3354) 0.002). This lower risk was independent of other baseline
Age years 59.6 (13.2) 58.9 (16.0) risk factors. In contrast, the use of fibrates was not associ-
Female sex 183 (50.6%) 1564 (46.6%)
ated with a lower risk of death (aRR  1.29; 95% CI Race
White 250 (69.3%) 2107 (63.4%) 0.85, 1.95). Figure 1 presents the adjusted cumulative
Black 79 (21.9%) 939 (28.3%) survival functions for statin users and non-users. TheOther 32 (8.9%) 275 (8.3%)
lower mortality among patients using statins comparedHistory of coronary
artery disease 153 (43.3%) 1022 (31.6%) to patients not using these medications appears to have
History of CVDa 170 (52.5%) 1460 (48.5%) begun approximately two months after entry into theUndernourished 52 (14.7%) 651 (20.2%)
cohort. The association between statin use and reducedHistory of diabetes 210 (59.0%) 1615 (49.1%)
Smoking status mortality was similar for hemodialysis and peritoneal
Never 196 (58.3%) 1755 (56.3%) dialysis patients (P 0.52 for test of interaction betweenFormer 98 (29.2%) 921 (29.6%)
dialysis modality and statin use).Current 42 (12.5%) 440 (14.1%)
Cholesterol mmol/L 5.46 (1.64) 4.97 (1.42) A higher risk of total mortality was associated with a
[211.1 (63.4) mg/dL] [191.7 (54.7) mg/dl]
history of diabetes, a history of CVD, increasing age,Triglycerides mmol/L 2.92 (2.22) 2.16 (1.52)
Albumin g/L 35 (6.0) 35 (6.0) white race, low serum albumin, undernourishment, and
not receiving a renal transplant during the follow-upData are mean (SD) or N (%).
a Defined as prior diagnosis of coronary artery disease, myocardial infarction, period (Table 2). Neither gender, dialysis modality, nor
coronary artery bypass, angioplasty, cardiac arrest, congestive heart failure, or
stroke cigarette smoking were associated with effects on total
mortality.
A total of 560 cardiovascular deaths occurred by the
end of the follow-up period. Among statin users, the
RESULTS cardiovascular-specific mortality rate was 61/1000 per-
son-years; the corresponding rate for non-users was 88/A total of 4065 patients were included in the DMMS
1000 person-years. The adjusted and unadjusted relativeWave 2 cohort. Of these, follow-up data were available
risk estimates of cardiovascular-specific death are pre-for 3716 patients. The remaining 349 patients were ex-
sented in Table 3. The use of statins was independentlycluded from our analysis because they were not appropri-
associated with a 37% lower risk of cardiovascular mor-ately assigned a unique USRDS identifier code, and thus
tality (aRR  0.63; 95% CI  0.44, 0.91; P  0.014). Intheir survival status could not be determined. Compared
contrast, the use of fibrates was not associated with ato the patients for whom follow-up data were available,
lower risk of cardiovascular death (aRR  1.41; 95%the excluded patients were less likely to be using statins
CI 0.79, 2.51). Among patients with pre-existing CVD,(3 vs. 9.7%), less likely to have CVD (36.9 vs. 43.9%),
statin use was strongly associated with lower cardiovas-were younger (mean age, 52 vs. 59 years), and had higher
cular mortality (aRR  0.50; 95% CI  0.32, 0.79). Intotal cholesterol levels (224 vs. 193 mg/dL).
contrast, in patients with no history of CVD, there wasCharacteristics of the study population are summa-
no association between statin use and cardiovascular
rized in Table 1. Of the 3716 patients in the cohort, 362
mortality (aRR 1.21, 95% CI 0.67, 2.17). The associ-
(9.7%) were being prescribed statins as of day 60 after ation between statin use and reduced cardiovascular
starting dialysis. Only 78 (2.1%) patients were prescribed mortality did not differ between hemodialysis and perito-
fibrates at the study start. Patients who were prescribed neal dialysis patients (P  0.87).
statins were relatively more likely to be white (69.3 vs. A higher risk of cardiovascular death was associated
63.5%), to have coronary disease (43.3 vs. 31.6%) and with a history of CVD, older age, white race, low serum
diabetes (59.0 vs. 49.1%), and to have higher levels of albumin, a history of diabetes, and treatment with perito-
serum cholesterol (211 vs. 192 mg/dL) and triglyceride neal dialysis (compared to hemodialysis; Table 3). Gen-
(2.92 vs. 2.16 mmol/L). Of the 3716 patients, 223 (6%) der, cigarette smoking, and malnourishment were not
were taking 15 or more medications at baseline. significantly associated with risk of cardiovascular death.
There were 1232 total deaths in the cohort through Additional analyses were performed with adjustments
July 1998. The mortality rate for patients using statins for use of aspirin, ACE inhibitors, beta-blockers and
was 143/1000 person-years; the mortality rate for non- calcium channel blockers. The addition of these covari-
users was 202/1000 person-years. The adjusted and unad- ates did not appreciably change the associations between
justed relative risk estimates for all-cause mortality asso- statin use and total and cardiovascular mortality (RR 
0.69 and RR  0.63, respectively); thus, these covariatesciated with various baseline demographic and clinical
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Table 2. All-cause mortality rates by statin use at baseline and other characteristics
Deaths Unadjusted RR Adjusted RR
Covariate (N1232) Person-years (95% CI) P value (95% CI) P value
Statin use
No 1142 5650 Referent Referent
Yes 90 628 0.70 (0.57, 0.87) 0.001 0.68 (0.53, 0.86) 0.002
Fibrate use
No 1200 6156 Referent Referent
Yes 32 123 1.33 (0.94, 1.89) 0.112 1.29 (0.85, 1.95) 0.238
Sex
Male 632 3334 Referent Referent
Female 600 2944 1.09 (0.97, 1.21) 0.147 1.08 (0.95, 1.24) 0.241
Race
White 897 3803 Referent Referent
Black 267 1853 0.62 (0.54, 0.71) 0.001 0.72 (0.61, 0.85) 0.001
Other 63 560 0.48 (0.37, 0.62) 0.001 0.55 (0.41, 0.74) 0.001
Modality
HD 720 3414 Referent Referent
PD 468 2302 0.96 (0.86, 1.08) 0.55 1.09 (0.95, 1.26) 0.220
Transplant 15 397 0.17 (0.10, 0.28) 0.001 0.30 (0.16, 0.59) 0.001
History of CVDa
No 338 3114 Referent Referent
Yes 750 2502 2.79 (2.45, 3.17) 0.001 1.65 (1.42, 1.93) 0.001
Smoking status
Never 608 3323 Referent Referent
Former 387 1648 1.28 (1.13, 1.46) 0.001 0.99 (0.85, 1.15) 0.926
Current 142 838 0.96 (0.80, 1.15) 0.652 1.18 (0.96, 1.46) 0.110
Undernourished
No 832 5032 Referent Referent
Yes 360 989 2.19 (1.93, 2.48) 0.001 1.49 (1.28, 1.73) 0.001
Prior Dx of diabetes
No 502 3194 Referent Referent
Yes 712 2959 1.52 (1.36, 1.70) 0.001 1.28 (1.11, 1.47) 0.001
Age per decade increase 1225 1.48 (1.42, 1.55) 0.001 1.33 (1.26, 1.40) 0.001
Albumin 1 g/dL decrease 1126 1.82 (1.67, 2.00) 0.001 1.50 (1.33, 1.70) 0.001
a Defined as prior diagnosis of coronary artery disease, myocardial infarction, coronary artery bypass, angioplasty, cardiac arrest, congestive heart failure, or stroke
Fig. 1. Adjusted Kaplan-Meier survival curves
modeling time to all-cause mortality. Solid line
refers to no statin use reported. Dashed line
refers to statin users.
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Table 3. Cardiovascular death rates by statin use at baseline and other characteristics
Deaths Unadjusted RR Adjusted RR
Covariate (N560) Person-years (95% CI) P value (95% CI) P value
Statins
No 522 5650 Referent Referent
Yes 38 628 0.65 (0.47, 0.90) 0.011 0.63 (0.44, 0.91) 0.014
Fibrates
No 544 6156 Referent Referent
Yes 16 123 1.46 (0.89, 2.39) 0.138 1.41 (0.79, 2.51) 0.249
Sex
Male 304 3334 Referent Referent
Female 256 2944 0.96 (0.81, 1.14) 0.650 0.98 (0.80, 1.20) 0.82
Race
White 409 3803 Referent Referent
Black 117 1853 0.60 (0.49, 0.74) 0.001 0.75 (0.59, 0.95) 0.02
Other 31 560 0.52 (0.36, 0.75) 0.001 0.55 (0.36, 0.86) 0.008
Modality
HD 321 3414 Referent Referent
PD 229 2302 1.03 (0.87, 1.22) 0.745 1.25 (1.02, 1.54) 0.034
Transplant 3 397 0.09 (0.03, 0.27) 0.001 0.11 (0.02, 0.73) 0.022
History of CVDa
No 127 3114 Referent Referent
Yes 366 2502 3.54 (2.89, 4.33) 0.001 1.96 (1.55, 2.48) 0.001
Smoking status
Never 279 3323 Referent Referent
Former 185 1648 1.33 (1.10, 1.60) 0.003 0.97 (0.78, 1.21) 0.8
Current 51 838 0.73 (0.54, 0.98) 0.035 0.87 (0.61, 1.23) 0.426
Undernourished
No 391 5032 Referent Referent
Yes 146 989 1.87 (1.55, 2.26) 0.001 1.24 (0.98, 1.57) 0.072
Prior Dx of diabetes
No 210 3194 Referent Referent
Yes 342 2959 1.73 (1.46, 2.06) 0.001 1.58 (1.28, 1.95) 0.001
Age per decade increase 555 1.56 (1.47, 1.67) 0.001 1.41 (1.29, 1.53) 0.001
Albumin 1 g/dL decrease 515 1.64 (1.43, 1.89) 0.001 1.29 (1.07, 1.57) 0.009
a Defined as prior diagnosis of coronary artery disease, myocardial infarction, coronary artery bypass, angioplasty, cardiac arrest, congestive heart failure, or stroke
are excluded from the final regression models presented Survival Study (4S) randomized hypercholesterolemic
patients with known coronary heart disease to simva-in Tables 2 and 3.
statin and placebo. There was a 35% reduction in the
risk of cardiovascular deaths, and a 30% reduction in
DISCUSSION the risk of all deaths [6]. The West of Scotland Coronary
Data from the USRDS DMMS Wave 2, a prospective Prevention Study Group randomized hypercholesterol-
cohort of incident dialysis patients, were analyzed to emic patients without CAD to pravastatin or placebo.
assess the association between use of HMG CoA-reduc- After five years of follow-up, the relative risk of cardio-
tase inhibitors and risk of death. Statin use was associated vascular-related death was reduced by 32% [8]. The Cho-
with a 32% lower risk of total mortality, independent lesterol and Recurrent Events Trial Investigators random-
of the effects of other characteristics known to affect ized normocholesterolemic patients following myocardial
mortality, including diabetes, age, prior cardiovascular infarction to pravastatin or placebo, and also found a
disease, and smoking. The use of statins was associated reduction in the relative risk of coronary-related deaths
with a similar lower risk of cardiovascular-specific mor- (RR  0.8) [7].
tality (aRR  0.63). In contrast, the use of fibrates was The mechanisms by which statins could reduce the
not associated with lower mortality (for total mortality, risk of cardiovascular mortality among ESRD patients
aRR  1.29, 95% CI  0.85, 1.95). are not fully understood. In the general population, ele-
Although to our knowledge there have been no prior vated serum cholesterol, and in particular elevation of
studies of the effect of HMG CoA-reductase inhibitors LDL cholesterol, is associated with higher cardiovascular
on cardiovascular outcomes among patients with ESRD, mortality [18]. A similar association between elevated
the association between use of statins and reduced risk LDL and increased cardiovascular disease among dial-
of cardiovascular mortality seen in this study is similar ysis patients has been reported [19], although other stud-
to that found in large, randomized controlled trials in ies have not confirmed this observation [20]. It is well
documented that statins cause significant reductions inthe general population. The Scandinavian Simvastatin
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LDL cholesterol. In non-ESRD patients, even those with patients without renal disease [reviewed in 29]. Statins
have anti-oxidant properties in vitro, and may modulateaverage cholesterol levels, statins can lower LDL choles-
terol levels by 25 to 40% [7, 9]; similar results have been atherosclerosis by preventing oxidation of LDL-choles-
terol [30].found in dialysis patients [10–12, 15, 16]. Reduction of
LDL cholesterol with statins or other therapies can in- When studied in vitro, statins have yet other effects that
in theory might mediate a cardioprotective effect in pa-hibit the development or progression of atherosclerosis
in the general population; it is possible that a similar tients [reviewed in 30]. Statins can interfere with the
uptake of LDL cholesterol into monocytes, thus inhib-effect may occur in ESRD patients.
Although the lower mortality among ESRD patients iting the formation of the foam cell, an important compo-
nent of the atherosclerotic plaque. They also have beenusing statins may be mediated in part by a reduction
in LDL cholesterol, most ESRD patients actually have shown to inhibit smooth muscle cell proliferation, which
is an important step in the progression of atherosclerosis.reduced total and LDL cholesterol levels when com-
pared to patients without renal disease [3–5, 21]. How- Statins may have direct antithrombotic properties, by
up-regulating endothelial nitric oxide production, by up-ever, these patients have other lipid abnormalities, in-
cluding elevations of serum IDL cholesterol [4, 22]. This regulating tissue plasminogen activator (tPA) activity,
and by inhibiting platelet aggregation. Thus, there are alipid component has been recognized as being highly
atherogenic, and independently associated with progres- number of mechanisms that could explain the association
between the use of statin and reduced cardiovascularsion of atherosclerosis in patients without ESRD [23, 24].
In the dialysis population, although its association with death in the ESRD patients in this study.
In addition to finding that statins were associated withcoronary disease has not been studied, elevated IDL cho-
lesterol has been associated with generalized aortic ath- a reduced rate of cardiovascular death, we also found
an association between statin use and reduced rates oferosclerosis [5]. Statins have been demonstrated to lower
IDL cholesterol in both non-ESRD patients [25, 26] and cardiovascular death (RR  0.72, 95% CI  0.52, 0.99).
There are several possible explanations for this finding.in patients on dialysis [12, 13]. Although previous studies
have not determined if reductions in IDL are associated One explanation is that statins truly reduced the risk of
non-cardiovascular death in this cohort. Although thiswith a reduction in mortality, it is possible that the reduc-
tion in mortality associated with statin use in the general has not been demonstrated in the general population
[6–8], dialysis patients have increased levels of oxidativepopulation is mediated, in part, by their ability to lower
IDL. This effect on IDL cholesterol also may explain the stress [29] that has been hypothesized to effect non-
cardiac functions such as immune responses to infection.lower mortality associated with statin use in the dialysis
patients in this study It is possible that the anti-oxidant properties of statins
could cause beneficial changes in these non-cardiac func-In addition to elevated IDL cholesterol, ESRD pa-
tients typically have reduced levels of HDL cholesterol. tions and result in improved non-cardiac survival. An-
other explanation for our finding is that there is misclassi-This abnormality is a well-described risk factor for ath-
erosclerosis [27], and has been associated with an in- fication of the cause of death. In this study, the cause
of death for a given patient was obtained from a formcreased risk of cardiovascular death in the general popu-
lation [18] and an increased risk of coronary artery submitted to the USRDS by the patient’s physician. A
previous study has suggested that, for patients with ESRD,disease among hemodialysis patients [20]. Many studies
have shown that statins can increase HDL cholesterol there is a poor correlation between cause of death re-
porting in the USRDS database and cause of death aslevels in non-ESRD patients [6–8, 28]. In dialysis patients,
some studies have shown an increase in HDL with statin reported in the patients’ death certificates [31]. However,
death certificates indicated that 40% of patients weretherapy [16], although other studies have not confirmed
this finding [12, 15]. These latter studies included rela- classified as having died of renal disease, whereas the
USRDS reporting system did not include renal diseasetively few subjects, and thus may have been underpow-
ered to detect small improvements in HDL. Therefore, it as a possible cause of death. Since few ESRD patients
die of renal failure per se, it is likely that the USRDSis possible that statins may protect against cardiovascular
mortality in dialysis patients by increasing HDL. reporting system is more accurate in determining the
true cause of death. Nevertheless, it is possible that someIn addition to having quantitative abnormalities in lipid
levels, dialysis patients often exhibit qualitative changes patients who died in our study were assigned an incorrect
cause of death. Such misclassification might introduce ain lipids as a result of uremia or the dialysis itself. Some
of these changes may promote the development of ath- bias into our estimates of relative risk of cause-specific
mortality, but it would not affect the observed associa-erosclerosis, and may be modified by statin therapy. In
particular, oxidative modification of LDL is thought to in- tion between statin use and reduced total mortality.
If patients who were prescribed statins were in bettercrease its atherogenic potential. In patients with ESRD,
levels of oxidized LDL may be increased compared to health than patients not taking statins, or had been re-
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ceiving more aggressive pre-ESRD medical care, then not able to assess the effect of statins on lipid levels
the reduced mortality observed in statin users might sim- in these patients, nor could we determine if the lower
ply be a result of their greater baseline health and/or mortality among statin users was related to changes in
superior pre-ESRD care, and not an effect of the medica- lipid levels. We also could not assess whether the associa-
tions themselves. However, there are several reasons tion between statin use and reduced mortality differed
why such a bias is unlikely to explain our findings. First, among patients with and without hyperlipidemia. How-
it could be expected that patients who were selected for ever, given the clinical and in vitro properties of statins
treatment with statins would actually have more severe described above, it is possible that statins could have
vascular disease than other patients, and thus be at higher cardioprotective effects even in ESRD patients without
risk of death for this reason than those not on statins. elevated total cholesterol or elevated LDL cholesterol.
In this cohort, statin users were, in fact, more likely In conclusion, the use of HMG-CoA reductase inhibi-
to have coronary disease than non-users (43 vs. 32%). tors is associated with reduced mortality among a cohort
Second, the associations between statin use and reduced of incident hemodialysis and peritoneal dialysis patients.
mortality were not appreciably changed by adjusting for This reduction in risk of death was independent of the
measures of pre-ESRD care, such as use of erythropoie- effects of other known risk factors, and was observed in
tin, duration of pre-ESRD nephrology care, and number both hemodialysis and peritoneal dialysis patients. The
of pre-ESRD nephrology visits (data not shown). Third, results suggest that statins may be effective in improving
the use of statins was associated with a reduced mortality survival in ESRD patients on dialysis.
even after adjustment for the effects of known risk fac-
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